OncoMatch/Clinical Trials/NCT04295863
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Is NCT04295863 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Nivolumab Standard and Pembrolizumab Standard for metastatic cancer.
Treatment: Nivolumab Standard · Pembrolizumab Standard · Nivolumab Extended · Pembrolizumab Extended — A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Cannot have received: immune checkpoint inhibitor
Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Of Chicago Medicine Comprehensive Cancer Center · Chicago, Illinois
- SSM Health Cancer Care · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify